Drugs / ACI-19764
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07463196 | Jan → Aug 2026 overdue | — | AC Immune SA | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-20 | AC Immune SA | Results AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 acimmune.com ↗
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive interim results from a Phase 1 first-in-human clinical study evaluating ACI-19764, its wholly-owned, orally administered small molecule inhibitor of the NLRP3 inflammasome. |
| 2026-07-07 | AC Immune SA | Results AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 acimmune.com ↗
Novel potent brain penetrant NLRP3 inhibitor ACI-19764 demonstrates efficacy in models of neuroinflammation |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-20 | AC Immune SA | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 acimmune.com ↗ |
| 2026-07-07 | AC Immune SA | AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 acimmune.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACI-19764 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07463196 ↗ |
| Action | Inhibit | “NLRP3 inhibitor” NCT07463196 ↗ |
| Route | Oral | “Participants receive a single oral dose A1 of ACI-19764” NCT07463196 ↗ |
| Target | NLRP3 | “NLRP3 inhibitor” NCT07463196 ↗ |